AT
ATGGF.US Actinogen Medical Limited
- Market cap
- USD 114M
- P/E
- -
- P/B
- 7.73x
- ROE
- -72.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ATGGF.US undervalued?
Graham numberThe Graham number of Actinogen Medical Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Actinogen Medical Limited fundamental analysis
No fundamental analysis for Actinogen Medical Limited yet.
Actinogen Medical Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and cha…
Full company profileActinogen Medical Limited financial statements
Actinogen Medical Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.42M | 3.30M | 4.86M | 3.52M | 1.98M | 3.64M | 4.89M | 9.93M | 5.49M | - |
| Gross Profit | 1.05M | 2.94M | 4.51M | 3.10M | 1.60M | 3.24M | 4.48M | 9.93M | 5.49M | -419K |
| Operating Income | -4.60M | -9.56M | -9.61M | -8.91M | -3.53M | -9.13M | -10.6M | -12.8M | -14.9M | -28.1M |
| EBITDA | -2.82M | -5.91M | -9.25M | -8.20M | -5.35M | -12.7M | -15.2M | -12.8M | -14.9M | -27.7M |
| Net Income | -3.19M | -6.23M | -9.89M | -5.33M | -3.92M | -9.50M | -10.8M | -13.0M | -14.7M | -15.4M |
| EPS | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 10.2M | 18.0M | 16.2M | 11.9M | 18.4M | 23.3M | 15.2M | 21.3M | 24.5M | 29.5M |
| Total Liabilities | 844K | 768K | 557K | 1.05M | 920K | 1.57M | 1.80M | 1.62M | 6.15M | 8.17M |
| Shareholders' Equity | 9.37M | 17.3M | 15.7M | 10.9M | 17.5M | 21.7M | 13.4M | 19.7M | 18.3M | 21.3M |
| Cash & Short-term Investments | 3.99M | 9.90M | 7.64M | 5.04M | 13.4M | 16.4M | 8.46M | 9.45M | 16.5M | 16.7M |
| Total Debt | - | - | - | 390K | 236K | 165K | 86.9K | 319K | 3.26M | 4.78M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.11M | -7.91M | -10.5M | -2.86M | -1.72M | -9.52M | -8.70M | -17.0M | -7.56M | -17.5M |
| Capital Expenditure | 1.03K | 274.00 | 22.8K | 22.8K | 6.19K | 2.94K | 36.6K | 8.16K | 38.0K | 9.28K |
| Free Cash Flow | -1.11M | -7.91M | -10.5M | -2.88M | -1.73M | -9.52M | -8.73M | -17.0M | -7.59M | -17.5M |
| Ratios | ||||||||||
| ROE | -34.1% | -36.1% | -63.1% | -49.0% | -22.4% | -43.7% | -80.2% | -66.2% | -80.3% | -72.0% |
| ROA | -31.2% | -34.6% | -61.0% | -44.7% | -21.3% | -40.8% | -70.7% | -61.2% | -60.2% | -52.0% |
| Net Profit Margin | -225.4% | -188.8% | -203.3% | -151.6% | -197.3% | -260.9% | -220.0% | -131.3% | -268.4% | - |
| Debt to Equity | - | - | - | 0.04x | 0.01x | 0.01x | 0.01x | 0.02x | 0.18x | 0.22x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Actinogen Medical Limited dividends
Actinogen Medical Limited has not paid dividends in the last 10 fiscal years.
Last stock split: 1041:1000 on Sep 27, 2023.
Who owns Actinogen Medical Limited
- Insiders 22.02%
- Institutions 2.85%
- Public & others 75.13%
- Shares outstanding 3.87B
- Free float 3.12B
Actinogen Medical Limited company profile
- Company name
- Actinogen Medical Limited
- Ticker
- ATGGF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 109 Pitt Street, Sydney, NSW, Australia, 2000
- Phone
- 61 2 8964 7401
- Website
- actinogen.com.au
About Actinogen Medical Limited
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Actinogen Medical Limited management
8- Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.MD, CEO & Director · born 1959
- Mr. William Edward Souter BCom, IPAA, LLB (Adel)Chief Financial Officer
- Dr. Dana C. Hilt M.D.Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board · born 1953
- Mr. Andrew B. Udell B.Sc., M.B.A.Chief Commercial Officer · born 1970
- Mr. Michael RobertsHead of Investor Relations & Corporate Communications
- Prof. Paul Edward Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.Head of Clinical Pharmacology & Lead Physician and Depression · born 1956
- Dr. Fujun Li Ph.D.Head of Manufacturing
- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963